Efficacy and Safety of Remibrutinib in Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis
Remibrutinib demonstrates significant efficacy and an overall favorable short-term safety profile for refractory CSU, though increased mild infections warrant monitoring. Larger, long-term studies and direct comparisons with omalizumab are needed.
Authors
- Valentina Lanari
- Anam Mirza (ORCID: https://orcid.org/0009-0008-7513-1837)
- Mahnoor Fatima (ORCID: https://orcid.org/0009-0000-9243-7960)
- Faiza Fatima (ORCID: https://orcid.org/0009-0006-4871-6595)
- Ahmed Raza (ORCID: https://orcid.org/0009-0007-1573-4188)
- Asma Javed (ORCID: https://orcid.org/0009-0001-3181-6016)
- Laiba Sarfraz
- Fatima Aslam (ORCID: https://orcid.org/0009-0006-7103-5552)
- Aleena Ihtasham
Institutions
- Services Institute of Medical Sciences (PK)
- King Edward Medical University (PK)
- University of Milan (IT)
- CMH Lahore Medical College and Institute of Dentistry (PK)
Publication Details
- Journal
- American Journal of Therapeutics
- Published
- 2025-10-17
- DOI
- https://doi.org/10.1097/mjt.0000000000002065
- Primary Topic
- Urticaria and Related Conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00